Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OPIANT PHARMACEUTICALS, INC.OPNT · Entity 115992 | Chief Commercial Officer | September 20, 2019 | September 20, 2019 |
| RxSight, Inc.RXST · Entity 1226 | Director · President and CEO | July 24, 2026 | July 25, 2026 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Chief Commercial Officer | March 17, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OPIANT PHARMACEUTICALS, INC.
Report date September 20, 2019 · Filed September 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,500 |
Reported balance
Holding disclosure · report date 2019-09-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 13,500 F1: 13,500 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of September 15, 2020, September 15, 2021, September 15, 2022 and September 15, 2023, subject to the Reporting Person continuing as a service provider through each such date. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.51 · Expires 2030-09-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-20 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One-fourth of the shares subject to the option vest on September 16, 2020 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 13,500 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of September 15, 2020, September 15, 2021, September 15, 2022 and September 15, 2023, subject to the Reporting Person continuing as a service provider through each such date.
F2: One-fourth of the shares subject to the option vest on September 16, 2020 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
RxSight, Inc.
Report date July 24, 2026 · Filed July 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 2,312,138 |
Reported balance
After 2026-07-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,312,138 · Balance 2,312,138 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty percent (20%) of the RSUs subject to the award shall vest on the one year anniversary of the grant date, twenty percent (20%) of the RSUs subject to the award shall vest on the two year anniversary of the grant date, and 60% of the RSUs subject to the award shall vest on the three year anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.19 · Expires 2036-07-23 | Direct | 571,286 |
Reported balance
After 2026-07-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-24 · Grant · Acquired 571,286 · Balance 571,286 F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and, thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 24, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty percent (20%) of the RSUs subject to the award shall vest on the one year anniversary of the grant date, twenty percent (20%) of the RSUs subject to the award shall vest on the two year anniversary of the grant date, and 60% of the RSUs subject to the award shall vest on the three year anniversary of the grant date.
F3: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Inducement Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, and, thereafter, one forty-eighth (1/48th) of the shares subject to the option shall vest each month on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 24, 2026.
Tarsus Pharmaceuticals, Inc.
Report date March 17, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,480 |
Ending reported balance
After 2026-03-19 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-17 · Sale · Disposed 4,286 · Balance 70,250 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 2 · 2026-03-18 · Sale · Disposed 4,330 · Balance 65,920 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Row 3 · 2026-03-19 · Sale · Disposed 4,440 · Balance 61,480 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2021 Filed Nov 8, 2021 22:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 11 | $28.11 | $309.21 |
DisclosureSEC source: 0001819790-21-000047 · wf-form4_163641175289229.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,092 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:49 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 100 | $28.03 | $2,803.00 |
DisclosureSEC source: 0001819790-21-000047 · wf-form4_163641175289229.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,103 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 542 | $27.07 | $14,672.48 |
DisclosureSEC source: 0001819790-21-000045 · wf-form4_163606700536434.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,203 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. F3 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $27.020 to $27.730. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:03 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 5,458 | $26.75 | $146,017.87 |
DisclosureSEC source: 0001819790-21-000045 · wf-form4_163606700536434.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,745 F1 · kind: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021. F2 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $26.020 to $27.015. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,593 | $0.45 Strike: $0.45 | $1,166.85 |
DisclosureSEC source: 0001819790-21-000031 · wf-form4_163165264472878.xml · derivative · entry 5 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772 Underlying: Common Stock · 2,593 shares Expires 2028-09-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,350 | $10.99 Strike: $10.99 | $47,806.50 |
DisclosureSEC source: 0001819790-21-000031 · wf-form4_163165264472878.xml · derivative · entry 4 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,989 Underlying: Common Stock · 4,350 shares Expires 2030-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | SaleCommon Stock | 2,593 | $22.15 | $57,434.95 |
DisclosureSEC source: 0001819790-21-000031 · wf-form4_163165264472878.xml · nonDerivative · entry 3 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,203 F1 · price: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $22.000 to $22.200. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 2,593 | $0.45 | $1,166.85 |
DisclosureSEC source: 0001819790-21-000031 · wf-form4_163165264472878.xml · nonDerivative · entry 2 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:51 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | Exercise / conversionCommon Stock | 4,350 | $10.99 | $47,806.50 |
DisclosureSEC source: 0001819790-21-000031 · wf-form4_163165264472878.xml · nonDerivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:55 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | GrantStock Option (right to buy) · Derivative | 40,999 | $0.00 Strike: $47.25 | $0.00 |
DisclosureSEC source: 0001209191-21-002741 · doc4.xml · derivative · entry 1 Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,999 Underlying: Common Stock · 40,999 shares Expires 2031-01-06 F1 · derivative.exercise_date: 25% of the option shares shall vest on January 7, 2022, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.